Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics. However, immune-related adverse events (irAEs) increase morbidity and mortality and thereby limit therapeutic utility. The real-world incidence of the entire spectrum of pulmonary irAEs has not been systematic...

Full description

Bibliographic Details
Main Authors:	Ugochi Ebinama, Ajay Sheshadri, Kartik Anand, Iyer Swaminathan
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2023-11-01
Series:	Journal of Immunotherapy and Precision Oncology
Subjects:	ror pd-1 pd-l1 adverse events
Online Access:	https://jipo.org/doi/pdf/10.36401/JIPO-22-38

Similar Items

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors  Based Combination Therapy
by: Xiaoyu GUO, et al.
Published: (2021-07-01)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
by: Luisa Maria Griewing, et al.
Published: (2021-03-01)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2021-11-01)

Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system
by: Hongxia Shi, et al.
Published: (2024-04-01)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2022-11-01)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
by: Lihu Gu, et al.
Published: (2019-06-01)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
by: Liting Sun, et al.
Published: (2023-04-01)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
by: Dan Zheng, et al.
Published: (2022-07-01)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
by: Yue Zhang, et al.
Published: (2022-04-01)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
by: Alessio Cortellini, et al.
Published: (2019-11-01)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
by: Peng-Fei Wang, et al.
Published: (2017-10-01)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022-03-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020-09-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
by: Ya-fang Huang, et al.
Published: (2019-10-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
by: Fengze Sun, et al.
Published: (2022-03-01)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01)

The PD-1:PD-L1 axis in Inflammatory Arthritis
by: Mary Canavan, et al.
Published: (2021-01-01)

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy
by: Dominique Delmas, et al.
Published: (2021-09-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
by: Enikő Sebestyén, et al.
Published: (2023-10-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
by: Huilin Ou, et al.
Published: (2022-08-01)

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
by: Adam Mor, et al.
Published: (2022-01-01)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
by: Hashem O. Alsaab, et al.
Published: (2017-08-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
by: Toshiya Fujisaki, et al.
Published: (2021-09-01)

Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
by: Hoda Z. Pourhassan, et al.
Published: (2019-09-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
by: Motoko Tachihara, et al.
Published: (2018-10-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)

Key differences between anti-PD-1/PD-L1 inhibitors
by: N. V. Zhukova, et al.
Published: (2022-06-01)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
by: Ching-Yao Yang, et al.
Published: (2020-06-01)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021-07-01)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
by: Chaoyue Su, et al.
Published: (2020-09-01)